SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) September 6, 2006  

 

AXONYX INC.

(Exact name of Registrant as Specified in its Charter)

 

 

Nevada

000-25571

86-0883978

(State or Other Jurisdiction
of Incorporation)

(Commission file Number)

(IRS Employer
Identification No.)

 

    

 

500 Seventh Avenue, 10th Floor, New York, New York 10018

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code (212) 645-7704

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

x

Soliciting material pursuant to Rule 14a-2 under the Exchange Act (17 CFR 240.14a-2)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events.

 

On September 6, 2006, the slide presentation attached hereto as Exhibit 99.1 will be presented by TorreyPines Therapeutics, Inc. at the Thomas Weisel Partners 2006 Healthcare Conference.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 6th day of September, 2006.

 

 

 

 

AXONYX INC.

 

  

 

  

 

By:        /s/ S. Colin Neill

 

Name: S. Colin Neill

 

Title: Chief Financial Officer

 

 

 

3